# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13D**

Under the Securities Exchange Act of 1934 (Amendment No. 12)\*

# Soleno Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share (Title of Class of Securities)

> 834203200 (CUSIP Number)

Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 17, 2024 (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  $\Box$ 

*Note:* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

00011	0. 05 12052			ruge i oi is pug				
1 N	lames of R	eporti	ng Persons					
Т	he Carlyle	Grou	p Inc.					
2 0	Check the Appropriate Box if a Member of a Group							
(;	a) 🗆 (	b) □						
3 S	EC Use Or	nly						
4 S	ource of Fi	unds (	(See Instructions)					
C	00							
5 C	Theck if dis	closu	re of legal proceedings is required pursuant to Items 2(d) or 2(e)					
	7							
		or Pla	ice of Organization					
	_							
Γ	Delaware	7						
		7	Sole Voting Power					
	BER OF		0					
	ARES FICIALLY	8	Shared Voting Power					
OWN	NED BY		2,003,101					
	ACH ORTING	9	Sole Dispositive Power					
	RSON							
W	/ITH	10	0 Shared Dispositive Power					
		10	Shared Dispositive Power					
			2,003,101					
11 A	ggregate A	mour	nt Beneficially Owned by Each Reporting Person					
2	,003,101							
		Aggr	regate Amount in Row (11) Excludes Certain Shares					
	_							
13 P		lace L	Represented by Amount in Row (11)					
13 1		1055 1	concerned by Amount III Row (11)					
	.99%							
14 T	ype of Rep	orting	; Person					
С	2O							

20511 10. 034205	200	150	1 age 2 01 15 pag
1 Names of I	Report	ting Persons	
Carlyle Ho	oldings	s I GP Inc.	
2 Check the		priate Box if a Member of a Group	
3 SEC Use C	Only		
4 Source of I	Funds	(See Instructions)	
00			
5 Check if di	isclosu	are of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	o or Pl	ace of Organization	
Delaware	7	Sole Voting Power	
	,		
NUMBER OF SHARES		0	
BENEFICIALLY	8	Shared Voting Power	
OWNED BY		2,003,101	
EACH REPORTING	9	Sole Dispositive Power	
PERSON			
WITH	10	0 Shared Dispositive Power	
	10		
		2,003,101	
11 Aggregate	Amou	Int Beneficially Owned by Each Reporting Person	
2,003,101			
12 Check if th	e Agg	regate Amount in Row (11) Excludes Certain Shares	
	Class	Represented by Amount in Row (11)	
4.99%			
14 Type of Re	portin	g Person	
СО			

	4205200	150	1 age 5 61 15 pa
1 Names	s of Report	ing Persons	
Carlyl	le Holdings	I GP Sub L.L.C.	
$\begin{array}{c c} 2 & Check \\ (a) & \Box \end{array}$	the Approp	priate Box if a Member of a Group	
3 SEC U	Use Only		
4 Source	e of Funds	(See Instructions)	
00			
5 Check	c if disclosu	re of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6 Citizer	nship or Pla	ace of Organization	
Delaw	vare		
	7	Sole Voting Power	
NUMBER	OF	0	
SHARES	S 8	Shared Voting Power	
BENEFICIA OWNED			
EACH	0	2,003,101 Sole Dispositive Power	
REPORTI PERSO	NG	Sole Dispositive I ower	
WITH		0	
	10	Shared Dispositive Power	
		2,003,101	
11 Aggreg	gate Amou	nt Beneficially Owned by Each Reporting Person	
2,003,	101		
		regate Amount in Row (11) Excludes Certain Shares	
	nt of Class I	Represented by Amount in Row (11)	
4.99%			
	of Reporting	g Person	
00 (L	Limited Lial	pility Company)	

JUSII NO. 034203	200	150	1 age 4 01 15 pag
1 Names of I	Report	ting Persons	
Carlyle Ho	ldings	s I L.P.	
2 Check the	Appro	priate Box if a Member of a Group	
(a) 🗆	(b) 🗆	]	
3 SEC Use C	Only		
4 Source of I	Funds	(See Instructions)	
OO			
5 Check if di	sclosu	are of legal proceedings is required pursuant to Items 2(d) or 2(e)	
_	o or Pl	ace of Organization	
Delaware	7	Sole Voting Power	
	/	Sole voting I ower	
NUMBER OF SHARES		0	
BENEFICIALLY	8	Shared Voting Power	
OWNED BY		2,003,101	
EACH REPORTING	9	Sole Dispositive Power	
PERSON		0	
WITH	10	Shared Dispositive Power	
11 Aggregate	A	2,003,101 Int Beneficially Owned by Each Reporting Person	
Aggregate	Amou	in Beneficiary Owned by Each Reporting Person	
2,003,101			
12 Check if th	e Agg	gregate Amount in Row (11) Excludes Certain Shares	
	Class	Represented by Amount in Row (11)	
4.99%			
14 Type of Re	portin	g Person	
PN			
PN			

/0511 1\0. C		150	1 age 5 61 15 pa
1 Nam	nes of Repo	orting Persons	
CG	Subsidiary	Holdings L.L.C.	
	ck the App	ropriate Box if a Member of a Group	
3 SEC	Use Only		
4 Sour	ce of Fund	ls (See Instructions)	
00			
5 Chee	ck if disclo	sure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6 Citiz	zenship or l	Place of Organization	
Dela	ware		
	7	7 Sole Voting Power	
NUMBE	R OF	0	
SHAR	ES S		
BENEFIC OWNEI			
EAC	Н	2,003,101 O Sole Dispositive Power	
REPORT PERSO	TING		
WIT	Н		
	10	) Shared Dispositive Power	
		2,003,101	
11 Aggi	regate Amo	ount Beneficially Owned by Each Reporting Person	
2,00	3,101		
12 Chec	ck if the Ag	ggregate Amount in Row (11) Excludes Certain Shares	
13 Perc	ent of Clas	s Represented by Amount in Row (11)	
4.99	%		
14 Type	e of Report	ng Person	
004	(I imited I	iability Company)	
001		aunity Company)	

2001	1 110. 0542052	-00	150	r uge o or 15 pug
1	Names of R	eport	ing Persons	
	TC Group,	L.L.C		
2	Check the A		priate Box if a Member of a Group	
3	SEC Use O	nly		
4	Source of F	unds	(See Instructions)	
	00			
5	Check if dis	sclosu	re of legal proceedings is required pursuant to Items 2(d) or 2(e)	-
6	Citizenship	or Pla	ace of Organization	
	Delaware			
		7	Sole Voting Power	
N	UMBER OF		0	
	SHARES NEFICIALLY	8	Shared Voting Power	
	WNED BY		2,003,101	
R	EACH EPORTING	9	Sole Dispositive Power	
	PERSON		0	
	WITH	10	Shared Dispositive Power	
			2,003,101	
11	Aggregate A	Amou	nt Beneficially Owned by Each Reporting Person	
	2,003,101			
12		Agg	regate Amount in Row (11) Excludes Certain Shares	
13		lass l	Represented by Amount in Row (11)	
	4.99%			
14	Type of Rep	orting	g Person	
	00 (Limite	d Lial	bility Company)	
	c (Linite		·····, -····k····)	

20511 NO. 054		150	r age / or ro pa
1 Names	of Report	ing Persons	
Carlyle	e Investme	nt Management L.L.C.	
	the Approp	priate Box if a Member of a Group	
3 SEC U	se Only		
4 Source	of Funds	(See Instructions)	
00			
5 Check	if disclosu	re of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6 Citizen	nship or Pla	ace of Organization	
Delawa	are		
Denant	7	Sole Voting Power	
NUMBER (	OF	0	
SHARES	8	Shared Voting Power	
BENEFICIAL OWNED B			
EACH	0	2,003,101 Sole Dispositive Power	
REPORTIN PERSON	NG	Sole Dispositive Fower	
WITH		0	
	10	Shared Dispositive Power	
		2,003,101	
11 Aggreg	gate Amou	nt Beneficially Owned by Each Reporting Person	
2,003,1	101		
12 Check i	if the Agg	regate Amount in Row (11) Excludes Certain Shares	
	t of Class I	Represented by Amount in Row (11)	
4.99%			
14 Type of	f Reporting	g Person	
00.04	imited Lial	bility Company)	
UU (LI		Jinty Company)	

JUSIF IND. 654203	5200	15D	Fage 8 01 15 pag
1 Names of	Reporting Persons		
Carlyle Ge	enesis UK LLC		
2 Check the	Appropriate Box if a Member of	of a Group	
(a) 🗆	(b) 🗆		
3 SEC Use (	Only		
4 Source of	Funds (See Instructions)		
00			
5 Check if d	isclosure of legal proceedings is	s required pursuant to Items 2(d) or 2(e)	
	p or Place of Organization		
Delaware	7 Octo Mating Decom		
	7 Sole Voting Power		
NUMBER OF	0		
SHARES BENEFICIALLY	8 Shared Voting Power		
OWNED BY	2,003,101		
EACH REPORTING	9 Sole Dispositive Pow	er	
PERSON	0		
WITH	10 Shared Dispositive Po	wer	
11	2,003,101 Amount Beneficially Owned by	Part David Brance	
11 Aggregate	Amount Beneficially Owned by	/ Each Reporting Person	
2,003,101			
12 Check if th	ne Aggregate Amount in Row (1	1) Excludes Certain Shares	
	Class Represented by Amount	n Row (11)	
4.99%			
	eporting Person		
OO (Limit	ed Liability Company)		

0001				ruge y or is puge				
1	Names of R	eport	ing Persons					
	Abingworth	1 LLP						
2	Check the A	Check the Appropriate Box if a Member of a Group						
	(a) 🗆	(b) □	]					
3	SEC Use O	nly						
4	Source of F	unds	(See Instructions)					
	00							
5	Check if dis	sclosu	re of legal proceedings is required pursuant to Items 2(d) or 2(e)					
6		or Pla	ace of Organization					
	<b>F</b> 1 1	1 *** 7 1						
	England and	d Wal	es Sole Voting Power					
		,						
	UMBER OF SHARES		0					
	NEFICIALLY	8	Shared Voting Power					
0	WNED BY		2,003,101					
R	EACH EPORTING	9	Sole Dispositive Power					
	PERSON		0					
	WITH	10	Shared Dispositive Power					
			2,003,101					
11	Aggregate A	Amou	nt Beneficially Owned by Each Reporting Person					
12	2,003,101	Δσσ	regate Amount in Row (11) Excludes Certain Shares					
12		1168	regule randult in New (11) Excludes Certain Shares					
10								
13	Percent of C	lass	Represented by Amount in Row (11)					
	4.99%							
14	Type of Rep	ortin	g Person					
	PN							

20511 100. 054205	-00	150	1 age 10 01 15 pa
1 Names of I	Report	ting Persons	
Abingwort	h Biov	ventures VII LP	
2 Check the	Appro	priate Box if a Member of a Group	
(a) 🗆	(b) □	]	
3 SEC Use C	Only		
4 Source of I	Funds	(See Instructions)	
00			
5 Check if di	isclosu	are of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	o or Pl	ace of Organization	
En den fer	1 337-1		
England an	nd Wal	Sole Voting Power	
	,		
NUMBER OF SHARES	0		
BENEFICIALLY	8	Shared Voting Power	
OWNED BY EACH		2,003,101	
REPORTING	9	Sole Dispositive Power	
PERSON		0	
WITH	10	Shared Dispositive Power	
		2,003,101	
11 Aggregate	Amou	int Beneficially Owned by Each Reporting Person	
2,003,101			
	e Agg	regate Amount in Row (11) Excludes Certain Shares	
13   Percent of 0	Class	Represented by Amount in Row (11)	
	C1055		
4.99%			
14 Type of Re	portin	g Person	
PN			

# **Explanatory Note**

This Amendment No. 12 to Schedule 13D ("Amendment No. 12") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on December 27, 2018 (as amended to date, the "Schedule 13D"), relating to the shares of common stock, par value \$0.001 per share (the "Common Stock"), of Soleno Therapeutics, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

13D

#### Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,142,314 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuer's quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof, (iii) 1,213,758 shares of Common Stock underlying a portion of the March 2022 Warrants, which are currently exercisable.

Reporting Person	Amount beneficially owned	Percent of class	Sole power to vote or to direct the vote	Shared power to vote or to direct the vote	Sole power to dispose or to direct the disposition	Shared power to dispose or to direct the disposition
The Carlyle Group Inc.	2,003,101	4.99%	0	2,003,101	0	2,003,101
Carlyle Holdings I GP Inc.	2,003,101	4.99%	0	2,003,101	0	2,003,101
Carlyle Holdings I GP Sub L.L.C.	2,003,101	4.99%	0	2,003,101	0	2,003,101
Carlyle Holdings I L.P.	2,003,101	4.99%	0	2,003,101	0	2,003,101
CG Subsidiary Holdings L.L.C.	2,003,101	4.99%	0	2,003,101	0	2,003,101
TC Group, L.L.C.	2,003,101	4.99%	0	2,003,101	0	2,003,101
Carlyle Investment Management L.L.C.	2,003,101	4.99%	0	2,003,101	0	2,003,101
Carlyle Genesis UK LLC	2,003,101	4.99%	0	2,003,101	0	2,003,101
Abingworth LLP	2,003,101	4.99%	0	2,003,101	0	2,003,101
Abingworth Bioventures VII LP	2,003,101	4.99%	0	2,003,101	0	2,003,101

The amount of Common Stock reported as beneficially owned above includes (i) 725,881 shares of Common Stock held of record by Abingworth Bioventures VII LP, (ii) 6,500 shares of Common Stock held of record by Andrew Sinclair for the benefit of Abingworth Bioventures VII LP, (iii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof, (iv) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, which are currently exercisable and (v) 34,049 shares of Common Stock underlying a portion of the March 2022 Warrants, which are currently exercisable.

The amount of securities disclosed excludes 480,617 shares of Common Stock underlying a portion of the March 2022 Warrants, which contain a provision prohibiting exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 4.99% of the total number of shares of Common Stock then issued and outstanding.

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the sole member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

(c) From October 14, 2024 through October 17, 2024, Abingworth Bioventures VII LP disposed of 499,047 shares of Common Stock in a series of open market transactions pursuant to the 10b5-1 Plan. Details by date, listing the number of shares of Common Stock disposed of and the weighted average price per share, are provided below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for each transaction.

Date	Shares Disposed Of	Price Range	Weighted Average Price Per Share
October 14, 2024	107,810	\$53.38 to \$55.24	\$54.4430
October 15, 2024	121,159	\$53.415 to \$55.00	\$54.2023
October 16, 2024	113,899	\$53.95 to \$55.00	\$54.5578
October 17, 2024	156,179	\$53.00 to \$54.05	\$53.4632

(d) None.

(e) As of October 17, 2024, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock.

#### 13D

# SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 21, 2024

#### The Carlyle Group Inc.

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Chief Financial Officer

# **Carlyle Holdings I GP Inc.**

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Managing Director and Chief Financial Officer

#### Carlyle Holdings I GP Sub L.L.C.

By: Carlyle Holdings I GP Inc., its sole member

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Managing Director and Chief Financial Officer

#### Carlyle Holdings I L.P.

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Managing Director

### CG Subsidiary Holdings L.L.C.

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Managing Director

# TC Group, L.L.C.

By: /s/ Anne Frederick, attorney-in-fact

Name: John C. Redett

Title: Managing Director

# Carlyle Investment Management L.L.C.

By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer

# Carlyle Genesis UK LLC

By: Carlyle Investment Management L.L.C., its sole member

By:	/s/ Anne Frederick, attorney-in-fact
Name:	John C. Redett
Title:	Chief Financial Officer

# Abingworth LLP

By: <u>/s/ John Heard</u> Name: John Heard Title: Authorized Signatory

#### Abingworth Bioventures VII LP

By: /s/ John Heard

Name: John Heard Title: Authorized Signatory